Q1 2024 Earnings Estimate for BioXcel Therapeutics, Inc. (NASDAQ:BTAI) Issued By HC Wainwright

BioXcel Therapeutics, Inc. (NASDAQ:BTAI) – Equities researchers at HC Wainwright increased their Q1 2024 earnings estimates for BioXcel Therapeutics in a research report issued to clients and investors on Monday, April 15th. HC Wainwright analyst R. Selvaraju now forecasts that the company will post earnings of ($0.69) per share for the quarter, up from their prior forecast of ($0.93). HC Wainwright currently has a “Buy” rating and a $11.00 target price on the stock. The consensus estimate for BioXcel Therapeutics’ current full-year earnings is ($2.52) per share. HC Wainwright also issued estimates for BioXcel Therapeutics’ Q2 2024 earnings at ($0.63) EPS, Q3 2024 earnings at ($0.59) EPS, Q4 2024 earnings at ($0.54) EPS and FY2024 earnings at ($2.42) EPS.

BTAI has been the topic of a number of other research reports. Bank of America decreased their price target on shares of BioXcel Therapeutics from $8.00 to $7.00 and set a “buy” rating on the stock in a research note on Wednesday, March 13th. Canaccord Genuity Group cut their price objective on shares of BioXcel Therapeutics from $18.00 to $7.00 and set a “buy” rating on the stock in a research report on Thursday, March 14th. Finally, UBS Group reiterated a “neutral” rating and set a $4.00 price objective (down previously from $9.00) on shares of BioXcel Therapeutics in a research report on Wednesday, February 21st. Four research analysts have rated the stock with a hold rating and three have given a buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $16.86.

BioXcel Therapeutics Stock Performance

BTAI stock opened at $2.55 on Thursday. BioXcel Therapeutics has a one year low of $1.91 and a one year high of $29.56. The company’s fifty day moving average price is $2.88 and its 200-day moving average price is $3.17. The company has a market capitalization of $77.98 million, a PE ratio of -0.41 and a beta of 0.40.

BioXcel Therapeutics (NASDAQ:BTAI) last posted its quarterly earnings results on Tuesday, March 12th. The company reported ($0.76) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.98) by $0.22. The business had revenue of $0.38 million during the quarter, compared to analyst estimates of $1.17 million. BioXcel Therapeutics had a negative net margin of 12,974.86% and a negative return on equity of 890.63%.

Institutional Trading of BioXcel Therapeutics

Institutional investors have recently modified their holdings of the company. Swiss National Bank boosted its stake in BioXcel Therapeutics by 9.2% in the 1st quarter. Swiss National Bank now owns 46,300 shares of the company’s stock worth $968,000 after purchasing an additional 3,900 shares in the last quarter. JPMorgan Chase & Co. lifted its stake in BioXcel Therapeutics by 15.9% during the 1st quarter. JPMorgan Chase & Co. now owns 13,606 shares of the company’s stock valued at $284,000 after acquiring an additional 1,870 shares during the period. Raymond James & Associates acquired a new stake in BioXcel Therapeutics during the 1st quarter valued at approximately $229,000. Bank of New York Mellon Corp lifted its stake in BioXcel Therapeutics by 2.9% during the 1st quarter. Bank of New York Mellon Corp now owns 58,386 shares of the company’s stock valued at $1,220,000 after acquiring an additional 1,637 shares during the period. Finally, MetLife Investment Management LLC lifted its stake in BioXcel Therapeutics by 57.0% during the 1st quarter. MetLife Investment Management LLC now owns 9,853 shares of the company’s stock valued at $206,000 after acquiring an additional 3,577 shares during the period. 30.68% of the stock is currently owned by institutional investors.

BioXcel Therapeutics Company Profile

BioXcel Therapeutics, Inc, a commercial-stage biopharmaceutical company, engages in utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. The company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices.